NCT02865031View on ClinicalTrials.gov

Dacorin for Proliferative Vitreoretinopathy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

August 31, 2016

Conditions
PVR
Interventions
DRUG

Decorin

Intravitreal Injection following ocular trauma to prevent scar tissue formation.

Trial Locations (1)

11431

Cairo University, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT02865031 - Dacorin for Proliferative Vitreoretinopathy | Biotech Hunter | Biotech Hunter